PDC Therapeutics to attend ESMO 2022 Congress for poster presentation on RS-0139’s ongoing clinical trial
22 August 2022
PDC Therapeutics, a biotech company developing targeted Polymer-Drug Conjugate technologies that are committed to advancing therapies with no compromise, announced the acceptance of RS-0139’s poster presentation at the ESMO Congress 2022 to be held in person on 9-13 September 2022 in Paris, France.
RS-0139 is the lead candidate of RS Research, a clinical-stage biotechnology start-up harvesting the superior therapeutic index that Sagitta© platforms are ready to offer. RS Research Medical Director Dr. Gülşah Nomak will present the candidates’ ongoing Phase Ia/Ib study at ESMO Congress 2022.
Poster Title: Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
Date: 12.09.2022
Poster No: 1200TiP
Presenter: Prof. Dr. Hakan S. Orer, Medical Pharmacology, Koc University Hospital; Dr. Gülşah Nomak, Medical Director, RS Research
The poster abstract is available online at the ESMO website.
PDC Therapeutics
PDC Therapeutics is a biotech company developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world. PDC Therapeutics’ proprietary clinically validated drug delivery technology Sagitta® can help discover and develop smart nanomedicines for therapies with no compromise.
For detailed information:
For media inquiries: pr@pdcbio.com
For technical inquiries: medicalinformation@pdcbio.com
www.pdcbio.com
